Effect of ubenimex on the immune system of patients with hematological malignancies

Abe, 1984, Effect of Bestatin on syngeneic tumors in mice, Gann, 75, 89 Adler, 1989, Interleukin-2 induction of lymphokineactivated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission, Blood, 74, 1690, 10.1182/blood.V74.5.1690.1690 Blomgren, 1987, Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder, Cancer Immunol, Immunother, 25, 41, 10.1007/BF00199299 Clement, 1984, Morphologic and phenotypic features of the subpopulation of Leu-2+ cells that suppresses B cell differentiation, J Immonol, 133, 2461 Corte, 1982, Human T cell subpopulations defined by a monoclonal antibody. I. A small subset is responsible for proliferation to allogeneic cells or to soluble antigen and for helper activity for B cell differentiation, J Immunol, 128, 16 Dickinson, 1985, Natural killer activity in childhood acute lymphoblastic leukemia, Br J, Hematol, 59, 45, 10.1111/j.1365-2141.1985.tb02962.x Fierro, 1988, In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity, Leukemia, 2, 50 Gatenby, 1982, Dissection of immunoregulatory subpopulations of T lymphocytes within the helper and suppressor sublineage in man, J Immunol, 129, 1997 Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA Lymphokine-activated killer cell phonomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155, 1823. Herberman, 1981, Natural killer cells: their role in defenses against disease, Science, 214, 24, 10.1126/science.7025208 Kaszubowski, 1980, T-lymphocyte subpopulation in peripheral blood and tissue of cancer patients, Cancer Res, 40, 4648 Kopersztych, 1976, cell-mediated immunity in patients with carcinoma, Cancer, 38, 114919, 10.1002/1097-0142(197609)38:3<1149::AID-CNCR2820380316>3.0.CO;2-X Kumano, 1985, Imbalance of T cell subsets in cancer patients and its modification with Bestatin, a small molecular immunomodifier, Tohoku J. Exp Med, 147, 125, 10.1620/tjem.147.125 Landay, 1983, Characterization of a phenotypically distinct subpopulation of Leu-2+ cells that suppresses T cell proliferative responses, J Immunol, 131, 2757 Lanier, 1983, Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens, J Immunol, 131, 1789 Lichtenstein, 1980, Comparison of immune derangements in patients with different malignancies, Cancer, 45, 2090, 10.1002/1097-0142(19800415)45:8<2090::AID-CNCR2820450816>3.0.CO;2-O Lotzova, 1987, Induction of NK cell activity against fresh human leukemia in culture with interleukin-2, J Immunol, 138, 2718 Mageed, 1987, Natural killer cells in children with acute leukemia, Cancer, 60, 2913, 10.1002/1097-0142(19871215)60:12<2913::AID-CNCR2820601212>3.0.CO;2-J Matera, 1983, Natural killer activity and low affinity E-rosettes in acute leukemias, Acta Hematol, 158 Mathé, 1989, Biologic and/or clinical observation on Bestatin therapy and/or prophylaxies of aging immuno-deficiency and spontaneous tumor appearance Mathé, 1989, Biologic and/or clinical observation on bestatin therapeutic action on CD4+ CD8− immuno-deficiency, on stem cell defect and marrow aplasia Nasrallah, 1983, Decreased natural killer cell activity in children with untreated acute leukemia, Cancer Res, 43, 5580 Oshimi, 1986, Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells, Blood, 68, 938, 10.1182/blood.V68.4.938.938 Ota, 1986, Results of investigation into prognosis after immunotherapy with Bestatin for acute nonlymphocytic leukemia in adults, Jpn J Cancer Chemother, 13, 1017 Rayner, 1985, Lymphokine-activated killer (LAK) cells, Cancer, 55, 1327, 10.1002/1097-0142(19850315)55:6<1327::AID-CNCR2820550628>3.0.CO;2-O Reinherz, 1982, Heterogeneity of human T4+ inducer T cells defined by a monoclonal antibody that delineates two functional subpopulations, J Immunol, 128, 463 Sorskaar, 1989, Increased natural killer cell activity and numbers of Leu-7 and Leu-11b (CD16)− positive cells in bone marrow of children in remission from acute lymphoblastic leukemia, Scand J Immunol, 29, 65, 10.1111/j.1365-3083.1989.tb01100.x Sorskaar, 1985, Natural killer cell activity of peripheral blood and bone marrow mononuclear cells from patients with childhood acute lymphoblastic leukemia, Acta Paediatr Scand, 74, 433, 10.1111/j.1651-2227.1985.tb10998.x Talmadge, 1986, The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers, Cancer Treat Rep, 70, 183 Talpaz, 1982, Studies of 32 natural killer cell activity and antibody-dependent cell-mediated cytotoxicity among patients with acute leukemia in complete remission, Cancer Immunol Immunother, 14, 96, 10.1007/BF00200175 Umezawa, 1976, Bestatin, an inhibitor of aminopeptidase B, produced by Actinomycetes, J Antibiotics, 29, 97, 10.7164/antibiotics.29.97 Yoda, 1983, Normalized natural killer (NK) cell activity in long-term remission of acute leukemia, Br J Hematol, 55, 305, 10.1111/j.1365-2141.1983.tb01251.x Zhou, 1990, Assay of lymphokine-activated killer activity generated from bone marrow cells of children with acute lymphoblastic leukemia, Blood, 75, 160, 10.1182/blood.V75.1.160.160